# FDA Approves Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

> fda · REPORTED · 2026-07-01

The FDA granted approval for Gilead's Trodelvy (sacituzumab govitecan) in first-line metastatic triple-negative breast cancer, expanding its label and positioning it earlier in the treatment paradigm for one of the most aggressive breast cancer subtypes. The European Commission also granted approval concurrently.

About Gilead Sciences (Trodelvy): Gilead Sciences is a global biopharmaceutical company; Trodelvy is an antibody-drug conjugate targeting Trop-2 approved for metastatic triple-negative and hormone receptor-positive HER2-negative breast cancers.

- Company: Gilead Sciences (Trodelvy)
- Sector: oncology
- Primary source: https://www.sec.gov/Archives/edgar/data/0001802768/000180276826000014/rprx-20260630rpplcpressxre.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.